Search Results
10
Everything
Search Filters
Organization
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
February 28, 2025 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI®...
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on...
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
February 20, 2025 02:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has...
Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 14, 2025 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2025 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the company approved the grant of equity awards to three new employees with a...
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
January 27, 2025 16:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan)...
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025 09:00 ET
|
Apellis Pharmaceuticals, Inc.
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net...
Apellis Announces Keli Walbert to Join the Board of Directors
January 10, 2025 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms....
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 07, 2025 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on...